



COVID-19 in Diabetes Patients

Padigela Rugvedh ^{a*}, Akshad Wadbudhe ^{a*} and Smita Damke ^{b^o}

^a *Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, India.*

^b *Department of Microbiology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, India.*

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i60B34795

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/79847>

Review Article

Received 18 November 2021

Accepted 20 December 2021

Published 23 December 2021

ABSTRACT

The 2019 coronavirus pandemic (COVID19) infected more than twenty-two point seven million human and resulted in the casualties of seven lakh ninety-five thousand people throughout the world. Diabetics are more prone to hitches and side effects caused by COVID19. The COVID19 pandemic overlaps with the already present high blood glucose pandemic that will produce bulky and suggestively more prone residents with high blood sugar levels and COVID19. This article will provide an outlook of the irrefutable suggestion for subordinate experimental products of COVID19 disease in diabetics compared to healthy individuals, including in specific group of individuals, such as broods, pregnant women, cultural minorities and folkloric. It also discusses similarities connecting COVID19 and it suggests that difficulty or pre-existing conditions in diabetics may exacerbate the infection process. Finally, this paper describes the outlook for chronic sequelae after COVID19 for more prone groups of diabetic individuals.

The year 2019 was hit by a very miserable disease which turned into, a contagion known as COVID19 caused by SARSCOV2 it is a ribonucleic B infective particle. The infected people have self-limiting symptoms, mature publics and the people with other related health disorders were under high hazard, also the impermanence rate was high among them. There were many and some were asymptomatic, the medical professionals advised them to isolate themselves and monitor the clinical symptoms.

^{*} Student;

^o Professor, H.O.D;

*Corresponding author: E-mail: padigelarugved44@gmail.com;

The insignificant warning sign affected role were given supportive care and isolation in ambulatory setting Mature patient role those with other health disorders were closely scrutinized until clinical recovery was achieved. The COVID19 pandemic was terminal.

Keywords: Diabetes; COVID-19; pandemic; morbidity; mortality.

1. INTRODUCTION

COVID19 are a cluster of ribo nucleic acid Viruses that is of single stranded and are largely disseminated in animals as well as humans throughout the world. However, many of the coronavirus infections are mild to moderate in humans and are of 2 types, Unembellished Grave Respirational Set of symptoms the deadly virus(SARSCOV) in 2002-2003 and (SARS-CoV-2) in December 2019 and thus the disease is called as COVID19.

On the other hand high blood glucose has been known to humankind since decades. Now its role in COVID19 has been seen to rise.

Diabetes is of four types I,II,III, IV

Covid19 is more prevalent in the second variant Diabetes Mellitus.

2. BACKGROUND

Although the exact pathophysiology is not clear for the severity and fatality for the people suffering with high blood glucose level second type.

High blood sugar level is one of the main cause for the impermanence and morbidity worldwide. Infections like influenza and pneumonia is very usual in older individuals and people suffering from second type high blood glucose disorder.

Few reports from China suggest that society with this disorder are at greater hazard of evolving severe contamination and mortality.

Diabetes is a chronic inflammatory disorder associated with many metabolism and blood vessel disturbances that will affect the immunity.

Because of increase in glucose concentration in blood and resistance of insulin there will be production of many end products and substances that favor inflammation there will be inflammation that accounts for worst outcome in individuals suffering from high blood glucose.

Many impairments of the immune system are associated with hyperglycemia and uncontrolled

diabetes causes inhibition of lymphocyte proliferative response to different kinds of stimuli and it also causes disturbances in the neutrophils.

Patients with diabetes have abnormal type of delayed hypersensitivity reaction and as the glucose concentration is high it favours the growth and replication of the influenza virus in lungs so this indicates that high glucose concentration in blood favors growth of viruses.

Patients with covid were reported to hospital with thrombocytopenia and higher D-dimer levels these were the causes of severity in diabetic people. [1] And, the other main cause for the severity of covid in diabetes is the presence of ACE2 receptors in the lungs these receptors when exposed to higher glucose levels cause entry of coronavirus into lungs however administration of insulin did not decrease the expression of ACE2 towards coronavirus [2].

In one of the largest studies published shows that hyperglycemia is present in 7.9% of the COVID19 individuals, Obesity is one of the major issue for COVID19 severity inpatient individuals with hyperglycemia which was not at all assessed [3].

There is ACE2 impairment in the pancreas is responsible for beta cell malfunction that results in increased blood glucose, these individuals are more susceptible to deadly COVID19 with physiological stress [4].

Increased blood glucose is related with immune malfunction, more prone to inflammation, decreased viral removal and association between RAAS and coronavirus may increase adherence of coronavirus to target cells and increase the severity of covid 19 [5]. People of increased blood glucose are at more prone to infections, namely flu and alveolar infections. This threat can be minimized, but not properly eradicated, by proper blood sugar balance. All individuals with high blood glucose (over 2 years of age) are advised to get a pneumococcal and flu shot every year. Not only that, diabetic patients are aggravated by respiratory viruses.

Indeed, diabetes is considered a significant threat aspect used for expiry in individuals disease-ridden with sickness, simple grave breathing set of symptoms coronavirus (SARS), and related coronaviruses.

Information on COVID19 in individuals with high blood glucose levels is currently limited. Diabetes was present in 42.3% of the 26 COVID19 deaths in Wuhan, China [6]. In a homework of one hundred and forty affected roles with COVID19 in Wuhan, China, high blood glucose was not a threat factor for infection progression. However, another study of one hundred and fifty patient roles (sixty-eight died and eight two in good health) that the number of comorbidities was a substantial forecaster of death. The scrutiny of eleven scholarships of workshop irregularities in COVID19 patients did not mention elevated blood sugar or diabetes as a predictor of severe disease. Even so, a small series of reports of 72,314 COVID19 gears in book form by the Chinese Center for Bug Rheostat and Stoppage exhibited an enlarged impermanence frequency among people with diabetes (general and diabetics)[7]. COVID19 is a recent contagion triggered by SARSCOV2, a new deadly living thing. High blood glucose (mainly second variant of diabetes) and increased blood glucose remain amid the main multiple issues in COVID19 affected role, foremost to deprived consequences. Intelligence suggest that the affected role with hyperglycemia and COVID19 are at amplified peril of emerging thoughtful problems, including grave lung anguish set of symptoms (ARDS), multiple tissue fiasco, and demise. Here, we travel possible automatic relations that may clarify the advanced illness and humanity observed in this enduring populace.

Patients with type 2 diabetes have augmented baseline irritation related to obesity and insulin confrontation along with other comorbidities counting HTN, obesity, CVD, dyslipidemia, and big stage. We appraisal the indication that type 2 diabetes with increased blood glucose is one of the factors leading to increased appearance of DCP2 in the lungs and other cluster of cells; DCP2 is the cell "binder" and the gateway for viruses. Already present long-lasting irritation with an augmented provocative reply to contamination and an growing epidemiologic consignment leading to an dangerous complete immune rejoinder is closely linked to the amplified sternness of COVID19. Founded on the obtainable sign, a board of specialists

recommends that harmless but hard blood sugar, blood pressure and lipid intensive care be achieved in patient role with second variant of diabetes, measures that might condense the cruelty of the disease. COVID19 if these occur. patient infected with the virus. Once an infection occurs, special attention should be paid to good blood sugar control using insulin and regular blood sugar monitoring [8]. Novel-start hyperglycemia is progressively existence stated as a sequence of cases throughout the COVID19 sickness, sometimes awarding with acute diabetic ketoacidosis. Numerous recent educations consume stated consequences for novel-commencement hyperglycemia compared with those with glycemic diabetes without COVID19.

In a reflective examination of one sixty six patients, Zhang et al. detected novel-beginning hyperglycemia in sixteen out of hundred of COVID19 cases twenty six out of sixteen but did not account for consequences distinctly from this group. Interestingly, there was no important rise in the risk of a composite outcome (MV, entry fee to sickbay. unit and death) were experiential in the diabetic group (equally original and already present) likened with those with normoglycemia. with COVID19. In divergence, found twenty-one percent (ninety four out of four fifty three) of affected role with original-beginning hyperglycemia and reported a significant increase in all-cause mortality. In the analysis at a median follow-up of 30 days, compared with individuals with non-hyperglycemia and COVID19. Equally, reported 29 patients (one seventy six out of six hundred and five) with new-onset diabetes mellitus whose complications on admission were meaningfully advanced at twenty eight days and all-cause mortality compared with the non hyperglycemic COVID19. In a reflective education of 69 affected role with innovative-commencement of hyperglycemia, Yang et al. found innovative-commencement of hyperglycemia as an self-governing analyst of demise level later multivariate analysis. KM survival analysis revealed suggestively complex impermanence in anew-beginning of hyperglycemia with COVID19. In a recent study by examined four hundred and thirteen affected and received five injections (twenty-one out of four hundred and thirteen) of original-start of hyperglycemia (with indicators of increased blood glucose), there were a substantial intensification unadorned COVID19 (Intensive care unit entry fee besides expiry) in people with a original progress of high sugar in fluid compartment of

body, equated to patient role with high blood sugar level [6]. Due to the novelty of COVID19 disease, there are no data available to inform specific treatments that may be helpful for diabetics with COVID19. Solitary single learning described giving an easy-going with mutually high blood glucose and COVID19, and extra scholarships might variation these fallouts. Six lessons finished recommendations for them with diabetes. Greatest of these recommendations stand built on former grades and proficient opinion. In an event tale study, patients might be frozen with drugs that kill bacteria (meropenem, linezolid), against viral drugs (ganciclovir, oseltamivir) and indicative action with drugs of indefinite origin. Four studies made specific recommendations supported by health systems for the treatment of patients with high blood glucose. The endorsements attention on patient role with diabetes, about of whom are not disease-ridden with COVID19, and affected role with COVID19. High blood glucose COVID19 patients need glycemic management and glycemic control; home-based appointments, personality-nursing, office visits with complex vision, mobile medicine; the usage of public radio and isolated persistent nursing. Registrars have wanted an instantaneous reduction in entirely redundant hospitalizations connected to high blood glucose, as well as to protect affected role from sickbay repair. Also pay attention to the diet and provide enough protein, exercise daily and get flu and pneumonia vaccines for these people. Suggestions for diabetic and COVID19 patients include controlling blood sugar levels, reducing drug side effects, avoiding hypoglycemic drugs, reducing the dose of diabetes drugs, and ending oral medicines, specifically Cotransporter2 metformin inhibitors and sodium glucose inhibitors for censoriously harsh affected role. These affected roles would be lonely for fourteen days or up until warning sign were resolve. They might want to stay hydrated, treat symptoms with acetaminophen, inhale vapor, measure blood sugar and ketones in diabetics if fever is associated with high blood sugar, and use blood sugar. insulin instead of oral hypoglycemic agents. In one training, hydroxychloroquine (HCQ) was suggested for the reason that it was approved for the dealing of high blood glucose in Bharat. Additionally, more research is needed on high blood glucose and COVID19, a smaller group with proven substantial death.[9] People with diabetes have an overall complex hazard of corruptions due to the repetitive disruption of their immunity that is present from birth. Whereas after birth immunity looks to be moderately

natural, individuals with high blood glucose have decreased cell eating by neutrophils, macrophages, and monocytes, with diminished regulatory activity, bacteriological and bacteria-killing effects of neutrophils, and immunity from birth facilitated. altered cell. As total impermanence from cardiovascular bug remains to decay in people with high blood glucose, lung disorder is becoming an gradually chief origin of bereavement in people with high blood glucose, with diseases conducive differently.

It is at this time strange whether people with high blood glucose are extra disposed to COVID19, but it has been suggested that the hazard of infection and serious illness is sophisticated. For example, the first three COVID-19-related deaths in Hong Kong all arisen in public by means of high blood glucose. In a huge succession, one seventy three out of one thousand ninety nine lab-confirmed COVID19 cases (sixteen percent) in China stayed off the record as serious. Sixteen out of one hundred people by means of serious illness have high blood glucose; in disparity, only six percent of the enduring nine twenty six mild cases had high blood glucose. The same, twenty four out of hundred people with unadorned ailment had hypertension, compared to thirteen out of hundred people of those with insignificant illness, suggesting an improved menace of antagonistic upshots in people with enduring environments such as high blood glucose.

It's still unclear why people with high blood glucose, high blood pressure, or other continuing conditions are extra strictly precious by COVID19, but one thinkable enlightenment comprises dipeptide hydrolase two. DCP2 is found in the heart, kidneys, lungs, and intestinal tissue, and by converting dipeptide hydroxylase II to dipeptide hydroxylase 1-7, it counteracts the effects of dipeptide hydroxylase II and encourages dilation of the arteries. Parallel to the virus that causes simple important lung disorder (SARSCOV), the new virus that causes COVID19 uses DCP2 on the surface of epithelial cubicles to muddle to and arrive disease-ridden cubicles. High blood glucose and conditions such as high blood pressure stay allied through stimulation of the DCP system in various cluster of cells. Additionally, individuals per high blood glucose too high blood pressure are regularly dried with DCP receptor antagonists and DCP receptor antagonist [10-19]. The moderately ill patients were hospitalized to monitor closely and were given isotonic fluid resuscitation if volume

depleted, oxygen supplementation to maintain SPO₂ not more than 96% and pulse oximeter was used to monitor.

Patient with risk to developing venous and thrombotic events were given anticoagulants. Severely ill patient were given prophylactic antiplatelet and wherever necessary anticoagulants. Severe COVID19. Developing secondary to cytokine storm causing rapid deterioration of the clinical status of positive patients

3. TREATMENT

Patients with renal failure were considered renal replacement therapy.

High flow nasal cannula O₂ or non-uniform ventilation were also given to patients who do not require intubation.

Self-pronging of awake patients receiving high flow nasal cannula improved oxygenation Rapid respiratory decompensation patients diagnosed with COVID19 were given V dose of tocilizumab or bevacizumab.

Vasopressor was also used to maintain mean arterial pressure between 60-65 mmHg.

Antibiotics were also used if there was any superimposed bacterial infection their use was stopped as soon as possible.

After doing all this and using the above methods for treatment the mortality was still high among other COVID19 patients which drew my attention towards studying these 2 drugs more as they were not studied enough (asirivimab and imdevimab for COVID19.

Newer experimental drugs like casitivismab and imdevimab.

Virus enters the cells via SARSCOV2 spike glycoprotein interacting with DCP2 angiotensin altering catalyst two receptor which is commonly expressed in the lower respiratory tract casitivismab and imdevimab (REGNCOV2) effectively reduce viral load in infected seronegative non hospitalized patients by binding to sites or the receptor binding sites glycoprotein of SARS COV 2 inhibiting to attach to human DCP2 receptor. It is given to all the outpatients greater 12 years age who are overweight or pregnant or have cardiovascular disease or

chronic respiratory disease or the hypertensive patients. Worse clinical outcome occurs in hospitalized patients who require high flow O₂ or mechanical ventilation.

casitivismab and imdevimab acted on the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B. 1.617.2), Epsilon (B.1. 427/429), Iota (B.1.526), Kappa (B.1.617.1), Variants of SARSCOV 2.3

3.1 Adverse Effects

The use of casitivismab and imdevimab have led to anaphylactic reactions and infusion and injection related reactions in a few cases

3.2 Dosage and Administrations

Separately packaged vials of 120mg/ml each of casitivismab and imdevimab are available. As an alternative a co-formulated solution in 60mg/ml vials is available.

After the SARSCOV2 test results and within 10 days of COVID-19 symptoms onset the 2, antibodies have been authorized for administration together (A single IV infusion after dilution in 50,100,150 or 250 ml of normal saline at a max rate of 310ml/hr (180ml/hr if diluted in 50ml) containing an authorized dosage Regencon containing 600mg of casitivismab and 600mg of imdevimab).

The solution can be refrigerated for up to 36hrs or left at room temperature for up to 4 hrs including infusion time in case the solution can't be used immediately after dilution.

A diluted solution which has been refrigerated should sit at room temperature for 30 minutes before administration.

SC administration can be done in case IV infusion delays treatment.

So these suggest the drug is stable at low temperature and easy to use.

Antibody administration must be followed by monitoring the patient for hypersensitivity reactions for at least 1 hr after it.

3.3 Availability

Based on case counts and severity of outbreaks the US department of health and human services (hhs).

Advocates casitivimab and imdevimab to the state health departments.

3.4 Treatment

Anti viral drugs are given to hamper the reproductive cycle of the virus

EX: Remdesivir.

Corticosteroids are also given to reduce or control the inflammation caused by our immune system, if not given may cause CYTOKINE STORM which is more dangerous.

EX: Dexamethasone.

If the infection is not at all controlled then MONOCLONAL ANTIBODIES are given which supports the immune system to fight the disease
EX: Tocilizumab, Itolizumab.

4. CONCLUSION

COVID-19 associated with diabetes results in many severe complications. This article highlighted the effects and treatment of COVID associated with diabetes. The insignificant warning sign affected role were given supportive care and isolation in ambulatory setting Elderly patient role those with other health disorders were closely scrutinized until clinical recovery was achieved.

DISCLAIMER

The products used for this research are commonly and predominantly used products in our area of research and country. There is no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Tadic M, Cuspidi C, Sala C. COVID-19 and diabetes: Is there enough evidence? *J Clin Hypertens (Greenwich)*. 2020;22(6):943-948.
DOI: 10.1111/jch.13912. Epub 2020 May 29. PMID: 32472662; PMCID: PMC7300807.
2. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, Khare S, Srivastava A. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. *Diabetes Metab Syndr*. 2020;14(4):535-545.
DOI: 10.1016/j.dsx.2020.04.044. Epub 2020 May 6. PMID: 32408118; PMCID: PMC7200339.
3. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. *Diabetes Res Clin Pract*. 2020;162:108142.
DOI: 10.1016/j.diabres.2020.108142. Epub 2020 Apr 9. PMID: 32278764; PMCID: PMC7144611.
4. Cuschieri S, Grech S. COVID-19 and diabetes: The why, the what and the how. *J Diabetes Complications*. 2020;34(9):107637.
DOI: 10.1016/j.jdiacomp.2020.107637. Epub 2020 May 22. PMID: 32456846; PMCID: PMC7242955.
5. Clotman K, Twickler MB. Diabetes or endocrinopathy admitted in the COVID-19 ward. *Eur J Clin Invest*. 2020 Jul;50(7):e13262.
DOI: 10.1111/eci.13262. Epub 2020 May 24. PMID: 32383239; PMCID: PMC7262001.
6. Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. *Diabetes Res Clin Pract*. 2020;167:108382. DOI: 10.1016/j.diabres.2020.108382. Epub 2020 Aug 25. PMID: 32853686; PMCID: PMC7445123.
7. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. *Diabetes Metab Syndr*. 2020;14(3):211-212.
DOI: 10.1016/j.dsx.2020.03.002. Epub 2020 Mar 10. PMID: 32172175; PMCID: PMC7102582.
8. Rajpal A, Rahimi L, Ismail-Beigi F. Factors leading to high morbidity and mortality of

- COVID-19 in patients with type 2 diabetes. J Diabetes. 2020;12(12):895-908. DOI: 10.1111/1753-0407.13085. Epub 2020 Sep 2. PMID: 32671936; PMCID: PMC7405270.
9. Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes Res Clin Pract. 2020;166:108347. DOI: 10.1016/j.diabres.2020.108347. Epub 2020 Jul 22. PMID: 32711003; PMCID: PMC7375314.
 10. Ma RCW, Holt RIG. COVID-19 and diabetes. Diabet Med. 2020;37(5):723-725. DOI: 10.1111/dme.14300. Epub 2020 Apr 3. PMID: 32242990; PMCID: PMC7228343.
 11. Feldman EL, Savelieff MG, Hayek SS, Pennathur S, Kretzler M, Pop-Busui R. COVID-19 and Diabetes: A Collision and Collusion of Two Diseases. Diabetes. 2020;69(12):2549-2565. DOI: 10.2337/dbi20-0032. Epub 2020 Sep 16. PMID: 32938731; PMCID: PMC7679769.
 12. Acharya, Sourya, Samarth Shukla, and Neema Acharya. Gospels of a Pandemic- A Metaphysical Commentary on the Current COVID-19 Crisis. Journal of Clinical and Diagnostic Research. 2020;14(6):OA01-2. Available:https://doi.org/10.7860/JCDR/2020/44627.13774.
 13. Arora, Devamsh, Muskan Sharma, Sourya Acharya, Samarth Shukla, and Neema Acharya. India in 'Flattening the Curve' of COVID-19 Pandemic - Triumphs and Challenges Thereof. Journal of Evolution of Medical and Dental Sciences-JEMDS. 2020;9(43):3252-55. Available:https://doi.org/10.14260/jemds/2020/713.
 14. Bawiskar, Nipun, Amol Andhale, Vidyashree Hulkoti, Sourya Acharya, and Samarth Shukla. Haematological Manifestations of Covid-19 and Emerging Immuno haematological Therapeutic Strategies. Journal of Evolution of Medical and Dental Sciences-JEMDS. 2020;9(46):3489-94. Available:https://doi.org/10.14260/jemds/2020/763.
 15. Burhani, Tasneem Sajjad, and Waqar M. Naqvi. Telehealth - A Boon in the Time of COVID 19 Outbreak. Journal of Evolution of Medical and Dental Sciences-JEMDS. 2020;9(29):2081-84. Available:https://doi.org/10.14260/jemds/2020/454.
 16. Butola, Lata Kanyal, Ranjit Ambad, Prakash Kesharao Kute, Roshan Kumar Jha, and Amol Dattarao Shinde. The Pandemic of 21st Century - COVID-19. Journal of Evolution of Medical and Dental Sciences-JEMDS. 2020;9(39):2913-18. Available:https://doi.org/10.14260/jemds/2020/637.
 17. Dasari, Venkatesh, Kiran Dasari. Nutraceuticals to Support Immunity: COVID-19 Pandemic- A Wake-up Call. Journal of Clinical and Diagnostic Research. 2020;14(7):OE05-9. Available:https://doi.org/10.7860/JCDR/2020/44898.13843.
 18. Dhok, Archana, Lata Kanyal Butola, Ashish Anjankar, Amol Datta Rao Shinde, Prakash Kesharao Kute, and Roshan Kumar Jha. Role of Vitamins and Minerals in Improving Immunity during Covid-19 Pandemic - A Review. Journal of Evolution of Medical and Dental Sciences-JEMDS. 2020;9(32):2296-2300. Available:https://doi.org/10.14260/jemds/2020/497.
 19. Gawai, Jaya Pranoykumar, Seema Singh, Vaishali Deoraoji Taksande, Tessy Sebastian, Pooja Kasturkar, and Ruchira Shrikant Ankar. Critical Review on Impact of COVID 19 and Mental Health. Journal of Evolution of Medical and Dental Sciences-JEMDS. 2020;9(30):2158-63. Available:https://doi.org/10.14260/jemds/2020/470.

© 2021 Rugvedh et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/79847>